More on RHHBY
Data
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $54.19 |
|
|||
| Open | $54.38 | ||||
| 52 Wk High | $35.13 | ||||
| 52 Wk Low | $28.10 | ||||
| Day High | $55.39 | ||||
| Day Low | $54.32 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 2,421,115 | ||||
- New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus
- Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity
- New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools
- Roche Holding (ROG:SW) (RHHBY) PT Raised to CHF415 at Kepler Cheuvreux
- Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)
- Flatiron Health Attends the 2026 American Society of Genitourinary Cancers Symposium to Answer Oncology's Most Critical Questions
- FDA approves Genentech's Venclexta plus acalabrutinib for CLL treatment
- FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
- FDA Accepts New Drug Application for Genentech’s Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer
- Roche Holding (ROG:SW) (RHHBY) PT Raised to CHF340 at Berenberg
Entities mentioned with RHHBY
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- Industrial Production | View Related Stories »
- ARK | View Related Stories »
- JPMorgan | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
